Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lymphatic Diseases AND Leukemia AND Clofarabine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44356   clinical trials with a EudraCT protocol, of which   7382   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16 result(s) found for: Lymphatic Diseases AND Leukemia AND Clofarabine. Displaying page 1 of 1.
    EudraCT Number: 2015-001172-21 Sponsor Protocol Number: CLO05908 Start Date*: 2015-05-18
    Sponsor Name:Genzyme Japan K.K.
    Full Title: A Phase 1, Open-label, Multi-center Study of Clofarabine in Japanese Pediatric Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
    Medical condition: Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-001174-18 Sponsor Protocol Number: CLO21800205 Start Date*: 2015-05-18
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase I/II Dose-Escalation Study of Clofarabine in Combination with Etoposide and Cyclophosphamide in Pediatric Patients with Refractory or Relapsed Acute Leukemias
    Medical condition: Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-005798-36 Sponsor Protocol Number: HOVON100ALL/EORTC06083 Start Date*: 2009-08-31
    Sponsor Name:HOVON Foundation
    Full Title: Clofarabine added to prephase and consolidation therapy in acute lymphoblastic leukemia in adults.
    Medical condition: Primary previously untreated B or T-lineage ALL (excluding ALL with mature B-cell phenotype, but including Philadelphia positive or BCR-ABL positive ALL) or previously untreated T-LBL
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    17.0 100000004864 10043028 T-lymphoblastic lymphoma (Kiel Classification) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001173-41 Sponsor Protocol Number: CLO08808 Start Date*: 2015-05-18
    Sponsor Name:Genzyme Corporation
    Full Title: An Open-Label, Multi-Center Safety and Tolerability Pilot Combination Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Patients with Acute Lymphobla...
    Medical condition: Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-021719-18 Sponsor Protocol Number: KS-2009-003 Start Date*: 2011-12-02
    Sponsor Name:Hannover Medical School
    Full Title: Phase I/II study on cytarabine and idarubicine combined with escalating doses of clofarabine as induction therapy in patients with acute myeloid leukemia and high risk for induction failure (CIARA)
    Medical condition: Patients with acute myeloid leukemia (AML) and high risk for induction failure
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019119-39 Sponsor Protocol Number: GIMEMALAL1509 Start Date*: 2011-05-16
    Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
    Full Title: A multicenter Total Therapy Strategy for De Novo Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients
    Medical condition: De Novo Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001866-90 Sponsor Protocol Number: AALL1131 Start Date*: 2014-07-15
    Sponsor Name:Children's Oncology Group
    Full Title: Treatment of Patients for newly diagnoised High Risk B-Lymphoblastic Leukemia (B-ALL) Testing Clofarabine in the Very High Risk Stratum
    Medical condition: Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-012758-18 Sponsor Protocol Number: COALL09-05-04 Start Date*: 2010-09-09
    Sponsor Name:Universitätsklinikum Hamburg-Eppendorf
    Full Title: A randomized multi-center treatment study (COALL 08-09) to improve the survival of children with acute lymphoblastic leukemia on behalf of the German Society of Pediatric Hematology and Oncology
    Medical condition: acute lymphoblastic leukemia in children and adolescents 1 to ≤ 18 years of age
    Disease: Version SOC Term Classification Code Term Level
    12.1 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019742-12 Sponsor Protocol Number: GIMEMALAL1610 Start Date*: 2012-06-06
    Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
    Full Title: A Phase II study with a sequential clofarabine-cyclophosphamide combination schedule as salvage therapy for refractory and relapsed acute lymphoblastic leukemia (ALL) in adult patients
    Medical condition: Acute Lymphoblastic Leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-009457-13 Sponsor Protocol Number: StudyITCC020&I-BFMRelapsedAML Start Date*: 2009-07-30
    Sponsor Name:Erasmus MC
    Full Title: A Phase I/II study of clofarabine in combination with cytarabine and liposomal daunorubicin in children with relapsed/refractory pediatric AML
    Medical condition: Relapsed/refractory acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066638 Acute myeloid leukemia progression LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060558 Acute myeloid leukemia recurrent LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed) CZ (Completed) AT (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021944-17 Sponsor Protocol Number: ClAraC-SCT-01 Start Date*: 2011-06-27
    Sponsor Name:Hannover Medical School
    Full Title: Randomized, Multi-centre, Phase II Trial to compare the Event-Free Survival of Clofarabine / Ara-C (ClAraC) or of FLAMSA Treatment in Patients with High Risk AML or Advanced MDS scheduled for Allog...
    Medical condition: Patients with high risk acute myeloid leukemia (AML) or advanced myelodysplastic syndrome (MDS) scheduled for allogeneic stem cell transplantation (SCT).
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000018-39 Sponsor Protocol Number: AMLBFM2012 Start Date*: 2014-11-20
    Sponsor Name:Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH gGmbH)
    Full Title: Clinical trial for the treatment of acute myeloid leukemia in children and adolescents
    Medical condition: AML
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000142-34 Sponsor Protocol Number: ITCC-092/IST11028 Start Date*: 2020-09-15
    Sponsor Name:Princess Máxima Center for pediatric oncology
    Full Title: A Phase Ib study of Vyxeos® (liposomal daunorubicin and cytarabine) in combination with Clofarabine in children with relapsed/refractory AML, ITCC-092
    Medical condition: Relapsed or refractory pediatric acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10060558 Acute myeloid leukemia recurrent LLT
    21.1 100000004864 10081514 Acute myeloid leukemia refractory LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) AT (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005461-14 Sponsor Protocol Number: LD-VenEx Start Date*: 2022-04-20
    Sponsor Name:Righospitalet
    Full Title: The Nordic AML Group – LD-VenEx: PHASE II STUDY OF AZACITIDINE IN COMBINATION WITH LOW DOSE VENETOCLAX IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (INCLUDING EXPLORATORY EVALUATION OF EX VIVO DRUG SENS...
    Medical condition: Acute Myelogenic Leukemia is aggressiv leukemia and treatment i challenging specialy in patients not eligible for intensiv chemotherapy or relapsed after intensiv chemotherapy.In this study we will...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) DK (Trial now transitioned) FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003282-36 Sponsor Protocol Number: 123123 Start Date*: Information not available in EudraCT
    Sponsor Name:Västra Götalands Regionen
    Full Title: A Randomized, Multi-Center Phase III Trial comparing two conditioning regimens (CloFluBu and BuCyMel) in children with Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation.
    Medical condition: Acute myeloid leukemia (AML) in children
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) NO (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-004517-34 Sponsor Protocol Number: AMLSCT-BFM2007 Start Date*: 2010-01-13
    Sponsor Name:Hannover Medical School
    Full Title: Allogeneic stem cell transplantation for children, adolescents and young adults with relapsed or refractory AML Multi Center Therapy Concept
    Medical condition: Relapsed or refractory Acute Myeloid Leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    20.0 100000004865 10067859 Allogenic stem cell transplantation LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Aug 21 21:34:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA